Adenylyl cyclase: a new target for heart failure therapeutics.
Feldman
Arthur M
AM
D000067956:Adenylyl Cyclase Inhibitors; D000818:Animals; D002311:Cardiomyopathy, Dilated / Q000201:enzymology / Q000378:metabolism / Q000628:therapy*; D000242:Cyclic AMP / Q000096:biosynthesis; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D043802:GTP-Binding Protein alpha Subunits, Gq-G11; D015316:Genetic Therapy; D020962:Heterotrimeric GTP-Binding Proteins / Q000235:genetics; D051379:Mice; D008822:Mice, Transgenic; D009206:Myocardium / Q000201:enzymology; D011943:Receptors, Adrenergic, beta / Q000378:metabolism; D051552:beta-Adrenergic Receptor Kinases
D000067956:Adenylyl Cyclase Inhibitors; D004791:Enzyme Inhibitors; D011943:Receptors, Adrenergic, beta; D000242:Cyclic AMP; D017868:Cyclic AMP-Dependent Protein Kinases; D051552:beta-Adrenergic Receptor Kinases; D043802:GTP-Binding Protein alpha Subunits, Gq-G11; D020962:Heterotrimeric GTP-Binding Proteins